Page 40 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 40
Chapter 2
19. Dührsen U, Hüttmann A, Müller S, et al. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial). Blood. 2014;124(21):(Abstract 391).
20. Straus DJ, Pitcher B, Kostakoglu L , et al. Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood. 2015;126(23):(Abstract 578).
21. Ganesan P, Rajendranath R, Kannan K, et al. Phase II study of interim PET-CT-guided response- adapted therapy in advanced Hodgkin’s lymphoma. Ann Oncol. 2015;26(6):1170-1174.
22. Hertzberg MS, Gandhi MK, Butcher B, et al. Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG.) Blood. 2015;126(23):(Abstract 815).
23. Swinnen LJ, Li H, Quon A, et al. Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170(1):56-65.
24. Stewart DA, Kloiber R, Owen C, et al. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leuk Lymph. 2014;55(9):2064-2070.
25. Pardal E, Coronado M, Martín A, et al. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014;167(3):327-336.
26. Sehn LH, Hardy ELG, Gill KK, et al. Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood. 2014;124:392.
27. Kasamon YL, Wahl RL, Ziessmann HA, et al. Phase II study of risk adapted therapy of newly diagnosed, aggressive Non-Hodgkin Lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15(2):242-248.
28. Barrington SF, Mikhaeel NG. PET-scans for staging and restaging in diffuse large B-cell and follicular lymphoma. Curr Hematol Rep. 2016;11(3):185-195.
38
